← Leaderboards
Paul S Mischel
University Of California Los Angeles
$15,265,453
Attributed
$16,938,964
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,938,964 · 7
By mechanism
R01$8,478,230 · 3
OT2$5,333,113 · 1
U54$2,518,771 · 2
K08$608,850 · 1
Top collaborators
- Benjamin F Cravatt5 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Judith Cheryl Gasson$28,230,504
- Ichiro Nakano$7,010,147
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsMalignant NeoplasmsGlioblastomaMolecularPharmaceutical PreparationsResistanceSignal TransductionGeneticPathway InteractionsIn VitroTumor GrowthBiochemicalIn VivoGenesProteinsCancer PatientBaseGenomicsEffective TherapyProteomicsApoptosisNovel TherapeuticsMutation
Grant awards (37)
eDyNAmiC - STANFORD$1,670,644
OT2 · FY2025 · CA · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$670,026
R01 · FY2025 · CA · contact PI
eDyNAmiC - STANFORD$1,464,660
OT2 · FY2024 · CA · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$641,594
R01 · FY2024 · CA · contact PI
eDyNAmiC - STANFORD$1,137,403
OT2 · FY2023 · CA · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$666,928
R01 · FY2023 · CA · contact PI
eDyNAmiC - STANFORD$1,060,406
OT2 · FY2022 · CA · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$671,855
R01 · FY2022 · CA · contact PI
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.$696,619
R01 · FY2021 · CA · contact PI
The role of mTORC2 in reprogramming cancer cell metabolism$291,352
R01 · FY2020 · NS · contact PI
The role of mTORC2 in reprogramming cancer cell metabolism$45,060
R01 · FY2020 · NS · contact PI
The role of mTORC2 in reprogramming cancer cell metabolism$336,412
R01 · FY2019 · NS · contact PI
The role of mTORC2 in reprogramming cancer cell metabolism$336,412
R01 · FY2018 · NS · contact PI
The role of mTORC2 in reprogramming cancer cell metabolism$342,474
R01 · FY2017 · NS · contact PI
The role of mTORC2 in reprogramming cancer cell metabolism$344,750
R01 · FY2016 · NS · contact PI
Role of mTORC2 in GBM - development of a novel therapeutic mTOR kinase inhibitor$349,229
R01 · FY2015 · NS · contact PI
The Heterogeneity of Glioblastoma Multiforme and its Applications towards the Dev$349,354
U54 · FY2014 · CA · contact PI
Role of mTORC2 in GBM - development of a novel therapeutic mTOR kinase inhibitor$345,736
R01 · FY2014 · NS · contact PI
The Heterogeneity of Glioblastoma Multiforme and its Applications towards the Dev$339,145
U54 · FY2013 · CA · contact PI
Role of mTORC2 in GBM - development of a novel therapeutic mTOR kinase inhibitor$337,006
R01 · FY2013 · NS · contact PI
The Heterogeneity of Glioblastoma Multiforme and its Applications towards the Dev$365,361
U54 · FY2012 · CA · contact PI
Role of mTORC2 in GBM - development of a novel therapeutic mTOR kinase inhibitor$334,921
R01 · FY2012 · NS · contact PI
The Heterogeneity of Glioblastoma Multiforme and its Applications towards the Dev$364,827
U54 · FY2011 · CA · contact PI
Role of mTORC2 in GBM - development of a novel therapeutic mTOR kinase inhibitor$346,734
R01 · FY2011 · NS · contact PI
The Heterogeneity of Glioblastoma Multiforme and its Applications towards the Dev$381,173
U54 · FY2010 · CA · contact PI
DEVELOPMENT OF MICROFLUIDICS INTEGRATED NANOELECTRONIC SENSORS AS A DIAGNOSTIC TO$397,311
U54 · FY2009 · CA · contact PI
Glioblastoma - Molecular Analysis for Clinical Trials$338,768
R01 · FY2009 · NS · contact PI
Glioblastoma - Molecular Analysis for Clinical Trials$338,768
R01 · FY2008 · NS · contact PI
DEVELOPMENT OF MICROFLUIDICS INTEGRATED NANOELECTRONIC SENSORS AS A DIAGNOSTIC TO$321,600
U54 · FY2008 · CA · contact PI
Glioblastoma - Molecular Analysis for Clinical Trials$338,768
R01 · FY2007 · NS · contact PI
Glioblastoma - Molecular Analysis for Clinical Trials$348,886
R01 · FY2006 · NS · contact PI
Glioblastoma - Molecular Analysis for Clinical Trials$355,932
R01 · FY2005 · NS
Trk receptor mediated apoptosis of medulloblastoma cells$121,770
K08 · FY2005 · NS
Trk receptor mediated apoptosis of medulloblastoma cells$121,770
K08 · FY2004 · NS
Trk receptor mediated apoptosis of medulloblastoma cells$121,770
K08 · FY2003 · NS
Trk receptor mediated apoptosis of medulloblastoma cells$121,770
K08 · FY2002 · NS
Trk receptor mediated apoptosis of medulloblastoma cells$121,770
K08 · FY2001 · NS